Industry context
Scilex Holding Company [SCLX]
Last Updated 25 Jun 2026 @ 16:00 (Exchange is closed)
Last: $7.09
3.35%
0.82 (↑)
GaG Algo Score™
v1.0
Short
0.82 (↑)
Medium
1.03 (↑)
Long
0.42 (↑)
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 50.14% | 50.14% | 0.00% |
| Loss % | -44.64% | -44.64% | 31.48% |
| Duration | 11.7d | 10d | 4.7d |
| Total Pivots Found | 4 |
| Gain/Loss Legs | 3 (1 Gain / 2 Loss) |
| Last Pivot | Bottom @ $4.30 on 2026-06-08 |
| Change since Last Pivot | $2.79 (64.88%) |
Next Pivot Prediction Last: $7.09
| Predicted Next Type | Top |
| Predicted Price (Avg) | $6.46 |
| Predicted Price (Median) | $6.46 |
| Predicted Price Range (~68%) | $6.46 - $6.46 |
| Change to Avg Target | $-0.63 (-8.94%) |
| Predicted Date (Avg) | 2026-06-19 |
| Predicted Date Range (~68%) | 2026-06-14 - 2026-06-24 |
| Basis | Based on 1 historical gains (Avg: 50.14%, Median: 50.14%, StdDev: 0.00%) and duration (Avg: 11.7 days, StdDev: 4.7 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Significant gain for Scilex Holding Company, up 3.35%.
Scilex Holding Company (SCLX) stock price surged on Thursday after the stock rose $0.230 (3.35%) from the previous session on very low volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -0.46%. A total of 68 544 stocks were traded yesterday, valued at $485 977, 37 549 shares more than the previous day (30 995 shares traded). This is below the average volume for the stock at 140 466 shares traded per day.
Scilex Holding Company signals
There is no conclusive signals given from RSI. The price is above the short-term average yet below the long-term average, with the short-term average still below the long-term average; signals are mixed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (13.3%), medium- (13.3%), and long-term (13.3%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Scilex Holding Company Support & Resistance Levels
The stock is trading above the closest support level at $6.90. approximately $0.190 (2.68%) away. This suggests it is currently acting as a floor, approaching it.The sup dis das support s16.9 -
Scilex Holding Company Evaluation
- Short score: 0.82
- Medium score: 1.03
- Long score: 0.42
Ownership flow
GetAGraph InsiderPower
Transactions
37
Buy power
18.38M
Sell power
14.33M
Reliability
100/100
Buy / sell
1.28
Hist. corr.
0.51
Latest signal
Buy 2026-06-25
Director 14
Officer 10
Executive 6
Major holder 6
2026-04-17
Ma Stephen Hoi Officer
Buy 650 000
2026-04-17
Ji Henry Executive
Sell 650 000
2026-04-17
Ma Stephen Hoi Officer
Buy 650 000
2026-04-17
Ji Henry Executive
Sell 650 000
2026-04-16
Ji Henry Executive
Buy 3 250 000
2026-04-16
Ji Henry Executive
Buy 3 250 000
Relationship map
Correlation snapshot
Positioning pressure
Short interest pressure
Short interest
2.68%
Of outstanding shares
Short float
3.35%
Of tradable float
Days to cover
1.780
Short interest divided by average volume
Squeeze probability
14.60%
+44.98% change
Short positioning does not currently stand out as a dominant risk factor.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
11
EPS beats
2
EPS misses
5
Avg. surprise
-595.02%
Scilex Holding Company Estimated Earnings vs Actual Earnings
Actual EPS
Estimated EPS
Waiting
Q2/2023
Waiting
Q3/2023
Miss
Q4/2023
Miss
Q1/2024
Miss
Q2/2024
Beat
Q3/2024
Miss
Q4/2024
Miss
Q1/2025
Beat
Q2/2025
Waiting
Q3/2025
Scilex Holding Company Earnings History
| Date | Period | EPS estimate | Actual EPS | EPS surprise | Revenue estimate | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|---|
| 2025-08-12 | Q3/2025 | $-4.55 | - | Waiting | - | - | Waiting |
| 2025-05-14 | Q2/2025 | $-4.20 | $-2.26 | Beat 46.19% | 17.79M | 5.00M | Miss -71.87% |
| 2025-01-17 | Q1/2025 | $-0.170 | $-6.29 | Miss -3 600.00% | 17.87M | 14.44M | Miss -19.21% |
| 2024-12-24 | Q4/2024 | $-0.200 | $-0.630 | Miss -215.00% | 17.87M | 14.44M | Miss -19.21% |
| 2024-08-13 | Q3/2024 | $-6.99 | $-6.29 | Beat 10.01% | 16.17M | 16.37M | Beat 1.25% |
| 2024-05-13 | Q2/2024 | $-4.20 | $-9.09 | Miss -116.43% | 10.88M | 10.88M | Beat 0.00% |
| 2024-03-11 | Q1/2024 | $-7.34 | $-8.74 | Miss -19.07% | 11.43M | 13.46M | Beat 17.82% |
| 2023-11-14 | Q4/2023 | $-5.94 | $-22.03 | Miss -270.88% | 11.37M | 10.12M | Miss -10.99% |
| 2023-08-11 | Q3/2023 | - | $-5.59 | Waiting | - | 12.58M | Waiting |
| 2023-05-12 | Q2/2023 | - | $-0.220 | Waiting | - | 10.58M | Waiting |
| 2023-05-12 | Q1/2023 | - | $-0.217 | Waiting | - | 10.58M | Waiting |
| 2022-09-29 | Q3/2022 | - | $0.161 | Waiting | - | 11.38M | Waiting |
News flow
Latest company news
Market coverage
gurufocus.com Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Jun 25, 2026 prnewswire.com Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Jun 25, 2026 globenewswire.com Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026 Jun 16, 2026 globenewswire.com Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities Jun 12, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers General
Currency
USD
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of nonopioid therapies designed to alleviate both acute and chronic pain Its primary marketed offering is ZTlido 18 a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with postherpetic neuralgia a condition characterized by persistent nerve pain following shingles Beyond this the companys development pipeline includes SP102 a viscous gel corticosteroid for epidural administration currently undergoing Phase III trials for lumbosacral radicular pain Another candidate SP103 is progressing through Phase II trials for managing low back pain Furthermore SP104 a novel lowdose delayedrelease naltrexone hydrochloride formulation has successfully concluded Phase I clinical testing for the treatment of fibromyalgia Its corporate offices are situated in Palo Alto California Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics Inc
Navigation